Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[99mTc]HYNIC-NC siRNA
- Development stage
- Unknown
- Lead developer
- Harbin Medical University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
[99mTc]HYNIC-NC siRNA is a radiolabeled negative control small interfering RNA (siRNA) probe used in preclinical molecular imaging research. It consists of a non-targeting negative control siRNA sequence (which has no homology to the human genome) conjugated to the radionuclide technetium-99m (99mTc) via the bifunctional chelating agent hydrazinonicotinamide (HYNIC). This agent is primarily utilized as a negative control in single-photon emission computed tomography (SPECT) imaging studies to evaluate the specificity and biodistribution of target-specific 99mTc-labeled siRNA imaging probes (such as those targeting MDM2 or HABP1) in tumor-bearing animal models.
- Other names
- 99mTc-HYNIC-NC siRNA99mTc-HYNIC-NCsiRNA99mTc-HYNIC-control siRNA99mTc-HYNIC-control-siRNA[99mTc]Tc-HYNIC-NC siRNA
Beyond the preview
Go deeper on [99mTc]HYNIC-NC siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [99mTc]HYNIC-NC siRNA.